These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 31144772)

  • 1. Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities.
    Barone A; Casey D; McKee AE; Reaman G
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27809. PubMed ID: 31144772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
    Nakayama H; Matsumaru N; Tsukamoto K
    Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of the written request process on drug development in childhood cancer.
    Snyder KM; Reaman G; Avant D; Pazdur R
    Pediatr Blood Cancer; 2013 Apr; 60(4):531-7. PubMed ID: 23335552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the experience with pediatric written requests issued for oncology drug products.
    Akalu AY; Meng X; Reaman GH; Ma L; Yuan W; Ye J
    Pediatr Blood Cancer; 2021 Feb; 68(2):e28828. PubMed ID: 33245181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs.
    Zettler ME
    Expert Rev Anticancer Ther; 2022 Mar; 22(3):317-321. PubMed ID: 35051348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
    Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
    Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gap between pediatric and adult approvals of molecular targeted drugs.
    Nishiwaki S; Ando Y
    Sci Rep; 2020 Oct; 10(1):17145. PubMed ID: 33051474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.
    Zeitoun JD; Baron G; Vivot A; Atal I; Downing NS; Ross JS; Ravaud P
    Int J Cancer; 2018 Jan; 142(2):414-423. PubMed ID: 28929484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016.
    Zhou J; Vallejo J; Kluetz P; Pazdur R; Kim T; Keegan P; Farrell A; Beaver JA; Sridhara R
    J Natl Cancer Inst; 2019 May; 111(5):449-458. PubMed ID: 30085269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
    Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
    JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
    Yamashita K; Kaneko M; Narukawa M
    Eur J Clin Pharmacol; 2019 Sep; 75(9):1193-1200. PubMed ID: 31129731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of first-in-child trials of FDA-approved oncology drugs.
    Neel DV; Shulman DS; DuBois SG
    Eur J Cancer; 2019 May; 112():49-56. PubMed ID: 30928805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric oncology: regulatory initiatives.
    Hirschfeld S; Shapiro A; Dagher R; Pazdur R
    Oncologist; 2000; 5(6):441-4. PubMed ID: 11110594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives.
    Hirschfeld S; Ho PT; Smith M; Pazdur R
    J Clin Oncol; 2003 Mar; 21(6):1066-73. PubMed ID: 12637472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The new drug approvals of 1993, 1994, and 1995: trends in drug development.
    Kaitin KI; Manocchia M
    Am J Ther; 1997 Jan; 4(1):46-54. PubMed ID: 10423591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis.
    Zosso-Pavic M; Li Q; Atiek E; Wolfer A; Rohr UP
    Lancet Oncol; 2024 Jun; 25(6):770-778. PubMed ID: 38754450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
    Tibau A; Molto C; Ocana A; Templeton AJ; Del Carpio LP; Del Paggio JC; Barnadas A; Booth CM; Amir E
    J Natl Cancer Inst; 2018 May; 110(5):486-492. PubMed ID: 29244173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.